<DOC>
	<DOCNO>NCT01059734</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research study look biomarker expression bone marrow sample patient acute myeloid leukemia .</brief_summary>
	<brief_title>S9031-S9126-S9333-S9500-B Biomarker Expression Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Estimate distribution topoisomerase 2 ( TOP2 ) expression single nucleotide polymorphism ( SNPs ) patient newly diagnose acute myeloid leukemia ( AML ) . - Estimate distribution mutation TOP2 phosphorylation site ( SNP analysis ) patient . - Investigate whether expression TOP2 mutation TOP2 phosphorylation site vary patient disease characteristic patient . - Test whether TOP2 expression correlate complete remission rate , relapse-free survival , overall survival patient . - Conduct preliminary analysis estimate distribution TOP2 expression mutation TOP2 phosphorylation site ( SNP analysis ) patient relapse and/or refractory AML . - Investigate whether expression TOP2 mutation TOP2 phosphorylation site vary patient disease characteristic patient relapse and/or refractory AML . - Test whether TOP2 expression mutation TOP2 phosphorylation site differ previously untreated relapsed/refractory AML patient . OUTLINE : This multicenter study . Archived RNA specimens analyzed topoisomerase 2 transcriptional expression quantitative real-time polymerase chain reaction ( PCR ) mutation within TOP2 phosphorylation sit single nucleotide polymorphism analysis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia All subtypes allow ( except acute promyelocytic leukemia [ M3 ] ) Previously untreated OR relapsed/refractory disease Isolated RNA specimens bone marrow aspirate sample available patient participate SWOG9031 , SWOG9333 ( cytarabine/daunorubicin hydrochloride induction arm ) , SWOG9500 , SWOG9126 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
</DOC>